Discovery of a potent M5 antagonist with improved clearance profile. Part 1: Piperidine amide-based antagonists

  • Bioorg Med Chem Lett. 2022 Nov 15;76:128988. doi: 10.1016/j.bmcl.2022.128988.
Rory A Capstick  1 ,  David Whomble  1 ,  Douglas L Orsi  1 ,  Andrew S Felts  1 ,  Alice L Rodriguez  1 ,  Paige N Vinson  1 ,  Sichen Chang  1 ,  Anna L Blobaum  1 ,  Colleen M Niswender  2 ,  P Jeffrey Conn  2 ,  Carrie K Jones  1 ,  Craig W Lindsley  3 ,  Changho Han  4
Affiliations
  • 1. Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, USA; Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
  • 2. Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, USA; Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA; Vanderbilt Kennedy Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
  • 3. Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, USA; Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA; Department of Chemistry, Vanderbilt University, Nashville, TN 37232, USA; Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN 37232, USA. Electronic address: [email protected].
  • 4. Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, USA; Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. Electronic address: [email protected].
PMID: 36113671 DOI: 10.1016/j.bmcl.2022.128988
Abstract

The lack of potent and selective tool compounds with pharmaceutically favorable properties limits the in vivo understanding of Muscarinic Acetylcholine Receptor subtype 5 (M5) biology. Previously, we presented a highly potent and selective M5 antagonist VU6019650 with a suboptimal clearance profile as our second-generation tool compound. Herein, we disclose our ongoing efforts to generate next-generation M5 antagonists with improved clearance profiles. A mix and match approach between VU6019650 (lead) and VU0500325 (HTS hit) generated a piperidine amide-based novel M5 antagonist series. Several analogs within this series, including 29f, provided good on-target potency with improved clearance profiles, though room for improvement remains.

Keywords
Antagonist; M(5); Muscarinic acetylcholine receptor 5; mAChR.
Products